Citations

Clear

15 citation(s) found for "Patel, Krishna".

Family-Based Next-Generation Sequencing Study Identifies an IL2RG Variant in an Infant with Primary Immunodeficiency
Bandari, Aravind K. , Bhat, Sunil, Archana, MV, Yadavalli, Sunita, Rajagopalan, Pavithra, Madugundu, Anil K. , Madkaikar, Manisha , Reddy, Kavita S., Pandey, Akhilesh , Pandey, Akhilesh , Pandey, Akhilesh , Patel, Krishna , Reddy, Kavita, Muthusamy, Babylakshmi

Mayo Clinic

OMICS: A Journal of Integrative Biology | May 17, 2019 | Volume: 23 | Issue: 5 | Pages: 285-290

10.1089/omi.2018.0196 | PMID 31100039 Get It

Abstract Primary immunodeficiencies (PIDs) are a rare and heterogeneous group of inherited genetic disorders that are characterized by an absent or impaired immune system. In this report, we describe the use of next-generation sequencing to investigate a male infant with clinical and immunological manifestations suggestive of a PID. Whole-exome sequencing of the infant along with his parents revealed a novel nucleotide variant (cytosine to adenine substitution at nucleotide position 252) in the coding region of the interleukin 2 receptor subunit gamma ( IL2RG ) gene. The mother was found to be a carrier. These findings are consistent with a diagnosis of X-linked severe combined immunodeficiency and represent the first such reported mutation in an Indian family. This mutation leads to an asparagine to lysine substitution ( p.Asn84Lys ) located in the extracellular domain of IL2RG, which is predicted to be pathogenic. Our study demonstrates the power of next-generation sequencing in identifying potential causative mutations to enable accurate clinical diagnosis, prenatal screening, and carrier female detection in PID patients. We believe that this approach, which is not a current routine in clinical practice, will become a mainstream component of individualized medicine in the near future.
Identification of lnc RNA s associated with early‐stage breast cancer and their prognostic implications
Rao, Arunagiri Kuha Deva Magendhra , Patel, Krishna , Jyothiraj, Suneetha Korivi, Meenakumari, Balaiah, Sundersingh, Shirley , Sridevi, Velusami , Rajkumar, Thangarajan , Pandey, Akhilesh , Chatterjee, Aditi , Mani, Samson , Pandey, Akhilesh , Gowda, Harsha

Mayo Clinic

Molecular Oncology | April 8, 2019 | Volume: 13 | Issue: 6 | Pages: 1342-1355

10.1002/1878-0261.12489 | PMID 30959550 Get It

Breast cancer is the most common malignancy among women, with the highest incidence rate worldwide. Dysregulation of long noncoding RNA s during the preliminary stages of breast carcinogenesis is poorly understood. In this study, we performed RNA sequencing to identify long noncoding RNA expression profiles associated with early‐stage breast cancer. RNA sequencing was performed on six invasive ductal carcinoma (IDC) tissues along with paired normal tissue samples, seven ductal carcinoma in situ tissues, and five apparently normal breast tissues. We identified 375 differentially expressed lncRNAs (DElncRNAs) in IDC tissues compared to paired normal tissues. Antisense transcripts (~ 58%) were the largest subtype among DE lnc RNA s. About 20% of the 375 DE lnc RNA s were supported by typical split readings leveraging their detection confidence. Validation was performed in n = 52 IDC and paired normal tissue by qRT ‐ PCR for the identified targets ( ADAMTS 9‐ AS 2, EPB 41L4A‐ AS 1, WDFY 3‐ AS 2, RP 11‐295M3.4, RP 11‐161M6.2, RP 11‐490M8.1, CTB ‐92J24.3, and FAM 83H‐ AS 1). We evaluated the prognostic significance of DE lnc RNA s based on TCGA datasets and report that overexpression of FAM 83H‐ AS 1 was associated with patient poor survival. We confirmed that the downregulation of ADAMTS 9‐ AS 2 in breast cancer was due to promoter hypermethylation through in vitro silencing experiments and pyrosequencing.
Incidence and Outcomes of Chemotherapy and Radiation in Morbidly Obese Patients with Locally Advanced Lung and Esophageal Cancers: A Single-Institution Experience
Patel, Krishna , Stephens, Elisabeth K., Jatoi, Aminah , Miller, Robert C.

Mayo Clinic

Cancer Control | August 30, 2017 | Volume: 21 | Issue: 1 | Pages: 63-66

10.1177/107327481402100109 | PMID 24357743 Get It

MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases
Kerkar, Sid P., Wang, Zeng-Feng, Lasota, Jerzy , Park, Tristen, Patel, Krishna , Groh, Eric, Rosenberg, Steven A. , Miettinen, Markku

Mayo Clinic

Journal of Immunotherapy | April 19, 2016 | Volume: 39 | Issue: 4 | Pages: 181-187

10.1097/cji.0000000000000119 | PMID 27070449 Get It

Two cancer testis antigens, the New York esophageal squamous cell carcinoma-1 (NY-ESO-1) and the melanoma-antigen family A (MAGE-A), represent promising immunotherapy targets due to the low expression of these antigens in nonmalignant tissue. To assess overexpression patterns in various cancers, we performed a systematic immunohistochemical analysis for NY-ESO-1 and MAGE-A on tissue array samples of 3668 common epithelial carcinomas (CA) and germ cell tumors of high prevalence and mortality. Here, we find significantly higher expression of MAGE-A (>50% on tumor cells) compared with NY-ESO-1 in several CAs including cutaneous squamous cell carcinomas (SCC) (52.8%/2.8%), esophageal SCC (50%/0%), head and neck SCC (41.1%/<1%), bladder urothelial CA (40.4%/8.3%), cervical/anal SCC (37.5%/0%), lung SCC (34%/3.8%), lung adenocarcinomas (27.6%/3.9%), ovarian CA (26.4%/3.6%), endometrial CA (26.3%/1.3%), lung small cell CA (24.4%/2.4%), gastric adenocarcinomas (20%/4%), breast mucinous CA (19.3%/0%), hepatocellular CA (18.8%/1.2%), breast infiltrating ductal CA (16.4%/1.8%), colorectal adenocarcinomas (10.7%/<1%), cholangiocarcinomas (9.8%/0%), thymic CA (9%/4.5%), and mesotheliomas (7.9%/<1%). Furthermore, high expression of MAGE-A, but not NY-ESO-1, was seen in whole slide evaluations of an independent cohort of metastatic SCC (45.5%/3.6%) and metastatic CA (13.5%/0%) of various primaries with significantly higher expression of MAGE-A in metastatic SCC compared with other metastatic CA. MAGE-A is also more highly expressed in germ cell tumors, seminomas (69%/3.5%) and nonseminomas (40.1%/4.7%). In summary, MAGE-A is more highly expressed than NY-ESO-1 in a majority of human malignancies, and targeting MAGE-A may benefit a large number of patients.